CLINICAL CORNER: Watchman Appears Cost-Effective, Neuromodulation Data From NANS; BTG’s PneumRx
This article was originally published in Clinica
Executive Summary
Clinica’s Clinical Corner provides an update on the latest R&D news and developments in ongoing clinical trials of early-, late-stage and approved medical devices.
You may also be interested in...
Long-Term Analysis Shows Boston Scientific’s Watchman Device Saves Money
An analysis of pooled five-year data from the PROTECT AF and PREVAIL trials, show left-atrial appendage closure to prevent stroke in patients with atrial fibrillation is not only cost‐effective compared to treatment with warfarin and other anticoagulant drugs, but saves money over time.
Earnings Winners And Losers: BSX, BCR, NUVA, NVCR
Several big names in medtech announced their second-quarter sales and earnings in late July and early August. Here are some of the companies that impressed investors and others that raised some doubts.
Minute Insight: Bayer Launches Precision Health Unit To Focus On Digital Consumer Health
The pharma giant said the new division will help people take control of their own health care with digital products.